Similar results have been obtained by combining oxaliplatin with PD-1 or PD-L1 blockers in immunocompetent mice with subcutaneous MC38 or CT26 CRCs [26–28], PC3 prostate cancers [29], MOC1 HNSCCs [30], MB49 bladder tumors [31], H22 hepatocellular carcinomas [32], and MCA205 fibrosarcomas [33]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.